Description | This product is a neutralizing antibody that binds to Severe Acute Respiratory Syndrome Coronavirus 2. BD-243 is capable of specifically binding with SARS-CoV-2 and shows a good capacity to neutralize the SARS-CoV-2. |
Clonality | Monoclonal |
Host Species | Human |
Target Species | SARS-CoV-2 |
Epitope | RBD receptor binding domain |
Isotype | IgG1 |
Expression Species | HEK293F or CHO cell line |
Conjugation | Unconjugated |
Purity | >95% |
Endotoxin | <1 EU/mg |
Form | Liquid |
Purification | Protein A purified |
Sterility | 0.2 μM filtered |
Formulation | PBS, pH 7.4 |
Preservation | No preservatives |
Stabilizer | No stabilizers |
Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
Application | ELISA |
Application Notes | The SARS-COV-2 binding specificities of the antibodies were quantity by ELISA against the Spike protein and the RBD protein. Briefly, ELISA plates were coated by Spike or RBD proteins at 1 μg/mL and 0.01 μg/mL in PBS at 4°C overnight. After standard blocking and washing, 100 μL monoclonal antibody at 1 μg/mL was added and incubated at room temperature for 2 hours. After the incubation, the plates were washed and incubated with goat anti-human IgG (H+L)/HRP for 1 hour at room temperature with a concentration of 0.08 μg/mL. The absorbance at 450 nm was measured by a microplate reader after the chromogen solution was added. |
ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
WB | Western Blot Protocol |
FC | Flow Cytometry Protocol |
Target | SARS-CoV-2 |
Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
Research Area | Coronavirus Disease 2019 |
Related Disease | Coronavirus Disease 2019 |